PRIMARY STUDY
3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis
Key Findings: This mouse model of gastric inflammation finds that selective CB2 agonists have effective anti-inflammatory properties, and could lead to further development of targeted treatments for diseases such as inflammatory bowel disease (IBD).
Type of Study: Animal Study
Study Result: Positive
Research Location(s): France
Year of Pub: 2013
Cannabinoids Studied: Endocannabinoid (unspecified)
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1, CB2
Citation: Tourteau A, et al. 3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis. Bioorg Med Chem. 2013; 21:5383-94. doi: 10.1016/j.bmc.2013.06.010
Authors: Tourteau A, Andrzejak V, Body-Malapel M, Lemaire L, Lemoine A, Mansouri R, Djouina M, Renault N, El Bakali J, Desreumaux P, Muccioli GG, Lambert DM, Chavatte P, Rigo B, Leleu-Chavain N, Millet R
